Jefferies and BTIG initiated coverage of Freenome with buy ratings, citing the scale of the addressable market for its cancer screening approach and pointing to commercialization partnerships. The analysts noted that Freenome’s deals with Abbott and Roche support distribution and potential adoption pathways for its screening tests. While the reports emphasized market size and commercialization leverage, they also highlight how coverage decisions in diagnostics can hinge on partner validation as much as on pipeline performance at this stage. For the cancer detection field, the initiation reflects continued investor attention on multi-test screening strategies where partnerships can reduce go-to-market friction and increase the probability of reaching payer and provider workflows at scale.